Last updated 2026-07-26
- Raised $660k PIPE, Oct 2025
- Raised $3.9M Undisclosed Round led by Elcam Medical, Sep 2020
- Raised PIPE, May 2025
Total raised
$4.5M
Last: A Round 2020-10
Stage
Public
Founded
2013
Headcount
5
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear's TeaRx™ technology is a diagnostic platform intended for Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid. The first CE-IVD approved test based on the TeaRx™ platform is intended for the identification and monitoring of Dry Eye Syndrome (TeaRx™ DES). Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications, including TeaRx™ Red Eye for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis, and Allergic conjunctivitis.
Funding history · 6 rounds · $4.5M total
2025-10
PIPE
$660K
2025-05
PIPE
Undisclosed
2024-11
Reverse Merger
Undisclosed
2020-09
Undisclosed Round
$3.9M
★ Elcam Medical★ BIOLIGHT Life Sciences
2015-09
Grant
Undisclosed
2014-04
Grant
Undisclosed
Headcount over time
From 5 (2018-05) to 8 (2025-10) · +3 (+60%) · 10 points · source: Finder history + radar grounding
Q&A
- What is DiagnosTear's primary focus?
- DiagnosTear is an ophthalmic company developing diagnostic solutions for eye diseases through tear fluid analysis, utilizing its TeaRx™ technology platform for Point-of-Care Testing (POCT).
- When was DiagnosTear founded?
- DiagnosTear was founded in September 2013.
- What is the employee count for DiagnosTear?
- DiagnosTear has 1-10 employees.
- What was the amount and lead investor of DiagnosTear's A Round in October 2020?
- In October 2020, DiagnosTear raised $3,850,000 in an A Round, with Elcam Medical as a lead investor.
- Has DiagnosTear received any grants recently?
- In 2023, DiagnosTear received a grant of $270,000 from the Israeli Innovation Authority.
- What is the status of DiagnosTear as a company?
- DiagnosTear is currently a public company.
- Who is the CEO of DiagnosTear?
- Dr. Shimon Gross serves as the Chief Executive Officer of DiagnosTear.
Team · 9
Eran Eilat
Founder · Founder
Dr. Shimon Gross
Chief Executive Officer
Yifftach Biel
Chief Financial Officer
Dr. Oded Yogev
Head of Innovation
Yaacov Michlin
Chairman of the Board
Julia Reznick Zilberman
Director
Prof. David Zadok
Scientific Advisory Board
Dr. Ron Neumann
Scientific Advisory Board
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
Patents
Tags
eye-diseasesophthalmologydiagnosticsmedical-devicesnon-invasivemonitoringhealthcare-providersmedical-technologiespersonalizationclinics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bio-light.co.il/diagnos-tear/ |
|---|---|
| linkedin.com/company/27090167 | |
| YouTube | youtube.com/channel/UC7ppZLxB5fTTgulP3Xh1wHA |
Identifiers & details
| Legal name | DiagnosTear Ltd. |
|---|---|
| Founded | 2013-9 |
| Employees (exact) | 5 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | bio-light.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514733765 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-02-06 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | פלאוט מנחם 10 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-24 | רישום שעבוד |